The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
Open accessThe DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are usually associated with loss of dopaminergic neurons. Loss of substantia nigra neurons and presence of Lewy body inclusions in some of the remaining neurons are the hallmark pathology seen in the final stages of the disease. Attempts to correlate Lewy body pathology to either cell death or severity of clinical symptoms, however, have not been successful. While the pathophysiology of the neurodegenerative process can hardly be explained by Lewy bodies, the clinical symptoms do indicate a degenerative process located at the presynapse resulting in a neurotransmitter deficiency. Recently it was shown that 90% or even more of alpha-synuclein aggregates in DLB cases were located at the presynapses in the form of very small deposits. In parallel, dendritic spines are retracted, whereas the presynapses are relatively preserved, suggesting a neurotransmitter deprivation. The same alpha-synuclein pathology can be demonstrated for PD. These findings give rise to the notion that not cell death but rather alpha-synuclein aggregate-related synaptic dysfunction causes the neurodegeneration. This opens new perspectives for understanding PD and DLB. If presynaptic alpha-synuclein aggregation, not neuronal loss, is the key issue of the neurodegenerative process, then PD and DLB may eventually be treatable in the future. The disease may progress via trans-synaptical spread, suggesting that stem cell transplants are of limited use. Future therapies may focus on the regeneration of synapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD is associated with four cardinal motor symptoms, including tremors, rigidity, bradykinesia, and postural instability, alongside the characteristic shuffling and stooped posture of the “Parkinsonian gait” [46].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“It could be demonstrated that the presence of symptoms may be related to the involvement of defined regions as measured by the occurrence of Lewy bodies [47–49], supporting the observations that the a-synuclein aggregation pathology spreads through the brain involving anatomical structures sequentially [13].”
BackgroundAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“The discovery of mutations in the a-synuclein gene [77, 114, 156] and overexpression of a-synuclein [123] as being associated with Parkinson’s disease or dementia with Lewy bodies (DLB) strengthens the association between protein”
BackgroundParkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 2×
“Tremor at rest, rigidity, akinesia/bradykinesia and postural instability are the four cardinal features in Parkinson’s disease [60].”
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“association between the frequency and extension of tangles and Ab-plaques and the occurrence of the disease [55, 104], Terry et al.”
BackgroundChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“It was assumed that the cognitive impairment in AD is related to a synaptic failure [121, 124, 130].”
Background
Cited by
Items 301–400 of 664
Formation and Characterization of Zein-Based Oleogels
Tsung, K.-L., Ilavský, J., & Padua, G. W. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c00184 · Cited by 26
Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?
Roberts, B., Theunissen, F., Mastaglia, F. L., Akkari, P. A., & Flynn, L. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169364 · Cited by 25
“pounds [87], in addition to the production of ROS [88], free radicals [89], and downstream processes of mitochondrial dysfunction [90].”
BackgroundSharrad, D. F., Gai, W., & Brookes, S. J. (2013) · The Journal of Comparative Neurology · doi:10.1002/cne.23296 · Cited by 29
“…2000; Noskova et al., 2011), because evidence points toward presynaptic terminals as being the earliest sites disturbed (Wishart et al., 2006; Kramer and Schulz-Schaeffer, 2007; Scheff et al., 2007; Gray et al., 2009; Milnerwood and Raymond, 2010; Schulz-Schaeffer, 2010; Waites and Garner, 2011).”
BackgroundGodsave, S. F., Wille, H., Pierson, J., Prusiner, S. B., & Peters, P. J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.015 · Cited by 29
“PrPSc does not target synapses specifically Synapto-toxicity may be an important early event in several neurodegenerative diseases, including Alzheimer’s disease (Palop and Mucke, 2010; Schulz-Schaeffer, 2010).”
BackgroundChen, M., Yang, W., Li, X., Li, X., Wang, P., Yue, F., Yang, H., Chan, P., & Yu, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6445 · Cited by 34
Epigenetic regulation in the pathophysiology of Lewy body dementia
Chouliaras, L., Kumar, G. S., Thomas, A. J., Lunnon, K., Chinnery, P. F., & O'Brien, J. T. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101822 · Cited by 28
Neurodegeneration in Parkinson disease: Moving Lewy bodies out of focus
Schulz‐Schaeffer, W. (2012) · Neurology · doi:10.1212/wnl.0b013e318278b6a7 · Cited by 29
Self-citationBu, L.-L., Huang, K., Zheng, D., Lin, D., Chen, Y., Jing, X., Liang, Y., & Tao, E. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.575481 · Cited by 27
“LB pathology in αSynucleinopathies is not confined to the central nervous system (CNS).”
BackgroundIshaq, S., Shah, I. A., Lee, S., & Wu, B. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1464168 · Cited by 27
How many biomarkers to discriminate neurodegenerative dementia?
Sancesario, G. M., & Bernardini, S. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1051658 · Cited by 24
Berndt, N., Holzhütter, H., & Bulik, S. (2013) · FEBS Journal · doi:10.1111/febs.12480 · Cited by 26
Metals in Alzheimer’s and Parkinson’s Disease: Relevance to Dementia with Lewy Bodies
McAllum, E. J., & Finkelstein, D. I. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0809-5 · Cited by 27
“…implicated in PD pathology. α-synuclein-containing Lewy bodies and Lewy neurites are a major pathological feature of PD (Mattila et al. 2000; Schulz-Schaeffer 2010; Spillantini et al. 1998; Spillantini et al. 1997) and α-synuclein is capable of binding metals with copper binding with the…”
BackgroundEffects of Excess Brain-Derived Human α-Synuclein on Synaptic Vesicle Trafficking
Román‐Vendrell, C., Medeiros, A. T., Sanderson, J. B., Jiang, H., Bartels, T., & Morgan, J. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.639414 · Cited by 24
“Furthermore, synaptic aggregation of α-synuclein is highly correlated with cognitive deficits and dementia in DLB patients (Kramer and SchulzSchaeffer, 2007; Schulz-Schaeffer, 2010).”
BackgroundCan We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?
Engelender, S., Stefanis, L., Oddo, S., & Bellucci, A. (2022) · Movement Disorders · doi:10.1002/mds.29058 · Cited by 23
Kumar, S., Jangir, D. K., Kumar, R., Kumari, M., Bhavesh, N. S., & Maiti, T. K. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00430 · Cited by 24
Sánchez, E., Azcona, L. J., & Paisán‐Ruiz, C. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0846-2 · Cited by 24
Fatty Acid-Binding Protein 3 Expression in the Brain and Skin in Human Synucleinopathies
Oizumi, H., Yamasaki, K., Suzuki, H., Hasegawa, T., Sugimura, Y., Baba, T., Fukunaga, K., & Takeda, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.648982 · Cited by 23
“Among FABPs, FABP3 is expressed mainly in the heart but is distributed in the kidneys, skeletal muscle, aorta, lungs, mammary glands, placenta, testes, ovaries, adrenal grands, stomach and brain (Furuhashi and Hotamisligil, 2008; Schulz-Schaeffer, 2010).”
BackgroundLi, G., Chen, Z., Zhou, L., Yao, M., Luo, N., Kang, W., Chen, S., & Liu, J. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.09.015 · Cited by 22
Interaction between α-synuclein and tau in Parkinson's disease
Jellinger, K. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.10.006 · Cited by 22
Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats
Elson, J. L., Yates, A. G., & Pienaar, I. S. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1045-4 · Cited by 22
A Systematic Review of Extracellular Matrix-Related Alterations in Parkinson’s Disease
Chapman, M. A., & Sorg, B. A. (2024) · Brain Sciences · doi:10.3390/brainsci14060522 · Cited by 22
Early α-synuclein aggregation decreases corticostriatal glutamate drive and synapse density
Brzozowski, C. F., Challa, H., Gcwensa, N. Z., Hall, D., Nabert, D., Chambers, N., Gallardo, I., Millet, M., Volpicelli‐Daley, L. A., & Moehle, M. S. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106918 · Cited by 22
“In pathological states, α -syn forms toxic amyloid fibrils (Firbank et al., 2016; Froula et al., 2019; Yang et al., 2022), which localize to synaptic terminals in the cortex of postmortem DLB brain (Colom-Cadena et al., 2017; Schulz-Schaeffer, 2010) and neurites in the striatum (Duda et al., 2002).”
Kuznetsov, I. A., & Kuznetsov, A. V. (2016) · Mathematical Biosciences · doi:10.1016/j.mbs.2016.05.002 · Cited by 22
Chiu, P., Yang, F., Chiu, M., Lin, W.-C., Lu, C., & Yang, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-22647-6 · Cited by 22
Interactions between cell adhesion and the synaptic vesicle cycle in Parkinson’s disease
Chapman, M. A. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.04.029 · Cited by 23
“Indeed, synaptic dysfunction has been hypothesized by others as a potential cause of neurodegeneration in Parkinson’s disease, although the mechanisms have not been fully elucidated [17–19].”
BackgroundPET imaging of synaptic density in Parkinsonian disorders
Martin, S. L., Uribe, C., & Strafella, A. P. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25253 · Cited by 22
Safinamide for the treatment of Parkinson’s disease
Kandadai, R. M., Jabeen, S. A., Kanikannan, M. A., & Borgohain, R. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.968555 · Cited by 20
“There is accumulation of an insoluble protein a-synuclein in the area involved; forming Lewy bodies which may lead to cell damage [5].”
BackgroundHope, T. R., Selnes, P., Rektorová, I., Anderková, Ľ., Elfmarková, N., Balážová, Z., Dale, A. M., Bjørnerud, A., & Fladby, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217922 · Cited by 22
The Role of Xenobiotics and Trace Metals in Parkinson’s Disease
Bjørklund, G., Dadar, M., Chirumbolo, S., & Aaseth, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01832-1 · Cited by 21
Nitric Oxide a new player in L-DOPA-induced dyskinesia
Del-Bel, E. (2015) · Frontiers in Bioscience-Elite · doi:10.2741/e726 · Cited by 22
Dimerization propensities of Synucleins are not predictive for Synuclein aggregation
Eckermann, K., Kügler, S., & Bähr, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.002 · Cited by 22
Current Progress in the Development of Probes for Targeting α-Synuclein Aggregates
Zeng, Q., & Cui, M. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00877 · Cited by 19
Brain-Site-Specific Proteome Changes Induced by Neuronal P60TRP Expression
Manavalan, A., Mishra, M., Sze, S. K., & Heese, K. (2013) · Neurosignals · doi:10.1159/000343672 · Cited by 20
The role of α-synuclein in neurodegeneration — An update
Jellinger, K. A. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0013-1 · Cited by 23
Neuroimaging of Dementia with Lewy Bodies
Taylor, J., & O'Brien, J. T. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.001 · Cited by 19
Progressive changes in a recognition memory network in Parkinson's disease
Segura, B., Ibarretxe‐Bilbao, N., Sala‐Llonch, R., Baggio, H. C., Martí, M. J., Valldeoriola, F., Vendrell, P., Bargalló, N., Tolosa, E., & Junqué, C. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302822 · Cited by 22
Morgan, J. R., Medeiros, A. T., & Bubacco, L. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230289 · Cited by 19
Xie, J., Chen, S., Bopassa, J. C., & Banerjee, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-92738-3 · Cited by 18
Data-driven retrieval of population-level EEG features and their role in neurodegenerative diseases
Li, W., Varatharajah, Y., Dicks, E., Barnard, L. R., Brinkmann, B. H., Crepeau, D., Worrell, G. A., Fan, W., Kremers, W. K., Boeve, B. F., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae227 · Cited by 21
“Factors 2 and 4 demonstrated moderate AUC metrics in classifying AD-MCI from CN; again, the addition of factors 3 and 6, or all factors did not significantly improve classifying potential.”
InfluentialG Proteins, p60TRP, and Neurodegenerative Diseases
Heese, K. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8410-1 · Cited by 18
Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies
Krismer, F., Jellinger, K. A., Scholz, S. W., Seppi, K., Stefanova, N., Antonini, A., Poewe, W. H., & Wenning, G. K. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.05.005 · Cited by 19
“In parallel, loss of dendritic spines appears to accompany the presynaptic aSYN pathology in Dementiawith Lewy Bodies [29] and loss of dendritic spines was also reported for striatal neurons in post-mortem PD brains [30].”
BackgroundResultBrys, I., Bobela, W., Schneider, B. L., Aebischer, P., & Fuentes, R. (2016) · International Journal of Neuroscience · doi:10.3109/00207454.2016.1138296 · Cited by 19
“The occurrence of cytoplasmic inclusions named Lewy bodies in neurons of the nigrostriatal pathway and locus coeruleus is a biological hallmark of PD [4].”
BackgroundDiagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies
Bousiges, O., & Blanc, F. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.11.027 · Cited by 20
Lin, W., Lu, C.-H., Chiu, P., & Yang, S. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000510325 · Cited by 20
Bitencourt, A. L. B., de Campos, R. M., Cline, E. N., Klein, W. L., & Sebollela, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238920 · Cited by 21
“Parkinson’s disease (PD) is a neurodegenerative disorder associated with the abnormal aggregation of the neuronal membrane protein alpha synuclein (α-syn) (reviewed in Shulz-Schaeffer [93]).”
BackgroundWon, S.-Y., Park, J., You, S.-T., Hyeun, J.-A., Kim, H. K., Jin, B. K., McLean, C., Shin, E., & Kim, E. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05030-1 · Cited by 18
Access to the CNS: Biomarker Strategies for Dopaminergic Treatments
van den Brink, W. J., Palić, S., Köhler, I., & de Lange, E. C. M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2333-x · Cited by 20
“The pathology of the Parkinson’s disease is characterized with an extensive loss of dopamine neurons in the SN and accumulation of the protein α-synuclein in Lewy bodies within nerve cells in specific brain regions (11).”
Backgroundm6A mRNA methylation in human brain is disrupted in Lewy body disorders
Cruz, B. M. D. L., Gell, C., Markus, R., Macdonald, I. A., Fray, R. G., & Knight, H. M. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12885 · Cited by 18
Salem, H. A., Abu‐Elfotuh, K., Alzahrani, S., Rizk, N. I., Ali, H. S., Elsherbiny, N. M., Aljohani, A. A., Hamdan, A. M., Panneerselvam, C., Abdou, N. S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102420 · Cited by 17
“The key component of the Lewy Bodies is α -synuclein ( α -Syn) a neuronal protein whose misfolding can cause neurotoxicity and apoptosis of neuronal cells [2].”
BackgroundRapid FRET Assay for the Early Detection of Alpha-Synuclein Aggregation in Parkinson’s Disease
Yu, H., Feng, R., Chen, F., Wu, Z., Li, D., & Qiu, X. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00617 · Cited by 17
Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome
Chang, K. T., Ro, H., Wang, W., & Min, K. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.08.007 · Cited by 18
Neuropathology of Parkinson's Disease and Parkinsonism
Dickson, D. W. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041610 · Cited by 17
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders
Bolsewig, K., Bellomo, G., Hok‐A‐Hin, Y. S., Idrissi, I. A., Vermunt, L., Lleó, A., Alcolea, D. A., Sieben, A., Engelborghs, S., Simonsen, A. H., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04212-0 · Cited by 17
Bernard, K., Mota, J. A., Wene, P. V., Corenblum, M. J., Saez, J. L., Bartlett, M. J., Heien, M. L., Doyle, K. P., Polt, R. L., Hay, M., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114926 · Cited by 16
Servi, R., Akkoç, R. F., Aksu, F., & Servi, S. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106766 · Cited by 16
Impaired olfactory bulb neurogenesis depends on the presence of human wild-type alpha-synuclein
May, V. E. L., Nuber, S., Marxreiter, F., Rieß, O., Winner, B., & Winkler, J. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.07.001 · Cited by 18
Novel therapies for combating chronic neuropathological sequelae of TBI
Ikonomović, M. D., Abrahamson, E. E., Carlson, S. W., Graham, S. H., & Dixon, C. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.021 · Cited by 16
“Accumulation of a-synuclein aggregates in presynaptic terminals impairs synaptic function (Kramer and Schulz-Schaeffer, 2007; Schulz-Schaeffer, 2010) and this may contribute to chronic neurodegeneration after TBI exposure.”
Bartels, M., Weckbecker, D., Kuhn, P., Ryazanov, S., Leonov, A., Griesinger, C., Lichtenthaler, S. F., Bötzel, K., & Giese, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-45298-6 · Cited by 17
Zhang, M., Yang, S., Li, X.-C., Zhu, H., Peng, D., Li, B.-Y., Jia, T.-X., & Tian, C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i11.1055 · Cited by 18
Soraya, G. V., Ulhaq, Z. S., Shodry, S., Kusuma, M. A. S., Herawangsa, S., Sativa, M. O., Gustaf, A., Faridwazdi, D. A. N., Florentia, S. W., Raisa, N., et al. (2022) · Neurological Sciences · doi:10.1007/s10072-021-05829-4 · Cited by 16
“1 3 of dopaminergic neurons, particularly within the substantia nigra [3, 4].”
BackgroundOizumi, H., Yamasaki, K., Suzuki, H., Ohshiro, S., Saito, Y., Murayama, S., Sugimura, Y., Hasegawa, T., Fukunaga, K., & Takeda, A. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51610 · Cited by 18
Plum, S., Steinbach, S., Abel, L., Marcus, K., Helling, S., & May, C. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400030 · Cited by 20
Yan, R., Yang, C. S., & Zhang, X. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.01.007 · Cited by 18
Martínez, M. (2023) · Antioxidants · doi:10.3390/antiox12071373 · Cited by 15
Miteva, D., Vasilev, G., & Velikova, T. V. (2023) · Antibodies · doi:10.3390/antib12040081 · Cited by 18
“The most extensive and highly structured forms of α -syn aggregate are Lewy bodies, either dense or diffuse structures [71,72].”
Backgroundda Silva, M. I. O., Santejo, M., Babcock, I. W., Magalhães, A., Minamide, L. S., Won, S.-J., Castillo, E., Gerhardt, E., Fahlbusch, C., Swanson, R. A., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06630-9 · Cited by 16
E2 conjugating enzymes: A silent but crucial player in ubiquitin biology
Parashar, S., Kaushik, A., Ambasta, R. K., & Kumar, P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102740 · Cited by 15
Challenges in the Neuropathological Diagnosis of Dementias
Jellinger, K. (2013) · International Journal of Neuropathology · doi:10.7726/ijn.2013.1002 · Cited by 15
“, 2005) and in α-synucleinopathies, eg, Parkinson disease (PD) and dementia with Lewy bodies (DLB) (Schulz-Schaeffer, 2010), and by cholinergic neuronal and axonal abnormalities being present in aging and AD (Geula et al.”
BackgroundInfluentialBrys, I., Lopes‐Nunes, J., & Fuentes, R. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13568 · Cited by 16
“…nigra of rats has been used to model PD. Alpha-synuclein is the major component of the Lewy bodies (Recchia et al., 2004), the cytoplasmic inclusions found in neurons of the nigrostriatal pathway and locus coeruleus that are considered a key cellular hallmark of PD (Schulz-Schaeffer, 2010).”
MethodKumar, R., Kumari, R., Kumar, S., Jangir, D. K., & Maiti, T. K. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.7b01727 · Cited by 21
In Vitro Models of Brain Disorders
le Feber, J. (2019) · Advances in neurobiology · doi:10.1007/978-3-030-11135-9_2 · Cited by 18
Behavioral symptomatology and psychopharmacology of Lewy body dementia
Tampi, R. R., Young, J. J., & Tampi, D. J. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00005-8 · Cited by 17
Gaspar, R., Idini, I., Carlström, G., Linse, S. S., & Sparr, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.622764 · Cited by 17
“The deposition of protein-rich aggregates and the spreading of the pathology throughout the brain are hallmarks of Parkinson’s disease (Schulz-Schaeffer, 2010).”
BackgroundSzelągowski, A., & Kozakiewicz, M. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/7759053 · Cited by 19
Новиков, Н. Ю., Brazhnik, E. S., & Kitchigina, V. F. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923110172 · Cited by 16
Ho, Y., Shen, M.-S., Tai, C., Li, H., Chen, J.-H., Liao, W., Chiu, P., Lee, I.-Y., Lin, C., & Hung, C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00507 · Cited by 16
“Lewy bodies and Lewy neurites formed by α-syn accumulation are involved in DLB pathophysiology (Campbell et al., 2000; Schulz-Schaeffer, 2010) and result in neurotoxicity and cell loss in the brain (Kim et al., 2014; Burre et al., 2015; Ingelsson, 2016).”
BackgroundKaranjin: a potential furanoflavonoid for neuroprotection
Gnanaraj, C., Govendan, M., Loo, C., Yong, Y. S., Sekar, M., Taib, C. N. M., Subramaniam, S. D., Shah, M. D., & Lee, W. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-09925-z · Cited by 17
“…again plays an important role in progression of the disease coupled with mitochondrial stress and dysfunction, ferroptosis of dopaminergic neurons, defected autophagy lysosomal system, failure of ubiquitin–proteasome system, and ultimately neuroinflammation (Schulz-Schaeffer 2010; Li et al. 2023).”
Ho, Y., Weng, J., Lin, C., Shen, M.-S., Li, H., Liao, W., Tsai, N., Hung, C., Lai, T., & Lee, I.-Y. (2018) · Behavioural Neurology · doi:10.1155/2018/4618716 · Cited by 16
Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson’s disease
Liu, X., Wang, Q., Yang, Y., Stewart, T., Shi, M. Y., Soltys, D., Liu, G., Thorland, E., Cilento, E. M., Hou, Y., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01133-6 · Cited by 14
Benzothiazole Amphiphiles Promote the Formation of Dendritic Spines in Primary Hippocampal Neurons
Cifelli, J. L., Dozier, L. E., Chung, T. S., Patrick, G. N., & Yang, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.701482 · Cited by 16
Jellinger, K. A. (2011) · Wiley eBooks · doi:10.1002/9781444341256.ch21 · Cited by 15
Beck, G., Shinzawa, K., Hayakawa, H., Baba, K., Sumi‐Akamaru, H., Tsujimoto, Y., & Mochizuki, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153789 · Cited by 14
Tan, Y., Ke, M., Huang, Z., Chong, C., Cen, X., Lu, J., Yao, X., Qin, D., & Su, H. (2019) · Aging and Disease · doi:10.14336/ad.2018.1216 · Cited by 14
Protective effect of thioredoxin reductase 1 in Parkinson’s disease
Liu, Z., ye, Q., Wang, F., Guo, Y., Cui, R., Wang, J., & Wang, D. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135457 · Cited by 13
Kuechler, E. R., Rose, A., Bolten, M., Madero, A. M., Kammoonah, S., Colborne, S., Gsponer, J., Morin, G. B., & Mayor, T. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104182 · Cited by 14
Michel, H. E., Tadros, M. M., Hendy, M. S., Mowaka, S., & Ayoub, B. M. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113015 · Cited by 13
Wang, Y. A., Snoek, B. L., Sterken, M. G., Riksen, J. A. G., Stastna, J. J., Kammenga, J. E., & Harvey, S. C. (2019) · BMC Genomics · doi:10.1186/s12864-019-5597-1 · Cited by 15
Behavioral Phenotyping in a Murine Model of GBA1-Associated Parkinson Disease
Do, J., Perez, G., Berhe, B. A., Tayebi, N., & Sidransky, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136826 · Cited by 12
Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects
Blanc, F., & Bousiges, O. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.008 · Cited by 11
The Aggregation Continuum of α-Synuclein and Its Relevance to Brain Aging
Rana, A., Nikam, T., Sreepathi, B., Saraf, S. A., & Awasthi, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00356 · Cited by 12
Brain O-GlcNAcylation: From Molecular Mechanisms to Clinical Phenotype
Uygar, B., & Lagerlöf, O. (2022) · Advances in neurobiology · doi:10.1007/978-3-031-12390-0_9 · Cited by 11
Pinder, P., Thomzig, A., Schulz‐Schaeffer, W., & Beekes, M. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.10.018 · Cited by 11
Self-citationProteasome inhibition leads to early loss of synaptic proteins in neuronal culture
Bajic, N., Jenner, P. G., Ballard, C. G., & Francis, P. T. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0816-9 · Cited by 15
“…(F = 5.287, p = 0.0168) and Dunnett’s multiple range test showed 5 lM lactacystin increased ubiquitination of proteins compared to control (p \ 0.05) structure, could interfere with neurotransmitter release and synaptic function and ultimately causing synaptic degeneration (Schulz-Schaeffer 2010).”
BackgroundInfluentialNeuroprotective function of Omi to α-synuclein-induced neurotoxicity
Chung, H., Islam, M. S., Rahman, M. M., & Hong, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104706 · Cited by 11
“Another pathological characteristic of PD is the presence of Lewy bodies, which mainly consist of aggregated αsynuclein (Baba et al., 1998; Spillantini et al., 1998; Schulz-Schaeffer, 2010).”
BackgroundFreezing and piercing of in vitro asymmetric plasma membrane by α-synuclein
Heo, P., & Pincet, F. (2020) · Communications Biology · doi:10.1038/s42003-020-0883-7 · Cited by 15
Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease
Franke, S. K., van Kesteren, R. E., Hofman, S., Wubben, J. A. M., Smit, A. B., & Philippens, I. H. C. H. M. (2016) · Neurodegenerative Diseases · doi:10.1159/000442574 · Cited by 11
Potential biofluid markers for cognitive impairment in Parkinson’s disease
Chen, J., Liang, C., Wang, F., Zhu, Y., Zhu, L., Chen, J., Liu, B., & Yang, X. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00592 · Cited by 10
Inhibiting mtDNA transcript translation alters Alzheimer's disease‐associated biology
Gabrielli, A. P., Novikova, L., Ranjan, A., Wang, X., Ernst, N. J., Abeykoon, D., Roberts, A., Kopp, A., Mansel, C. O., Qiao, L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14275 · Cited by 11
Lilamand, M., Clery, J., Vrillon, A., Mouton‐Liger, F., Cognat, E., Gaubert, S., Hourrègue, C., Martinet, M., Dumurgier, J., Hugon, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113488 · Cited by 10
“However, the aggregates of α-syn in Lewy bodies and Lewy neurites do not seem to play a role in the neuronal disturbances [27].”
BackgroundCory, M. B., Jones, C. M., Shaffer, K. D., Venkatesh, Y., Giannakoulias, S. G., Perez, R. M., Lougee, M. G., Hummingbird, E., Pagar, V. V., Hurley, C. M., et al. (2023) · Protein Science · doi:10.1002/pro.4633 · Cited by 10
Metadata
- Authors
- Schulz-Schaeffer, W. J.
- Venue
- Acta Neuropathologica
- Published
- 2010-06-20
- Volume
- 120
- Issue
- 2
- Pages
- 131-143
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC2892607
- OpenAlex
- W2033827101
- Cited by
- 627
- References
- 165
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 45 · 2023: 24 · 2022: 43 · 2021: 48 · 2020: 48 · 2019: 41 · 2018: 40 · 2017: 35 · 2016: 36 · 2015: 29 · 2014: 41 · 2013: 36 · 2012: 35
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Funders
- Volkswagen Foundation (ZN 2168)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- alpha-synuclein aggregation, Lewy bodies, dementia with Lewy bodies, Parkinson's disease, Parkinson's disease dementia, presynaptic dysfunction, synaptic pathology, neurotransmitter deficiency, neurodegeneration, trans-synaptic spread, stem cell transplantation, synapse regeneration
- MeSH terms
- Animals, Brain, Parkinson Disease, Synapses, Lewy Body Disease, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.